Experimental, epidemiological and clinical studies have demonstrated that vasopressin contributes to the progression of chronic kidney disease by imposing an increased burden on diseased nephrons, and to autosomal dominant polycystic kidney disease by promoting cyst growth. Vasopressin also has a role in the pathogenesis of diabetes mellitus and metabolic disorders. This Review describes the adverse effects of vasopressin and provides insights into vasopressin physiology that may be relevant to the understanding of these adverse effects.
- Lise Bankir
- Nadine Bouby
- Eberhard Ritz
